iRadimed (NASDAQ:IRMD) Share Price Breaks Above 50 Day Moving Average - What's Next?

Key Points

• iRadimed shares briefly moved above their 50-day moving average of $86.43, trading as high as $86.55 before closing at $85.88. The stock remains below its 200-day moving average of $90.79.
• Analyst sentiment is mixed but remains a consensus “Moderate Buy”, with a $120 target price; several firms recently downgraded the stock to “Hold.”
• The company exceeded quarterly earnings and revenue expectations, reporting $0.46 EPS and $20.47 million in revenue, while paying a quarterly dividend of $0.20 per share, equivalent to a 0.9% yield.

iRadimed Corporation (NASDAQ:IRMD - Get Free Report) shares passed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $86.43 and traded as high as $86.55. iRadimed shares last traded at $85.88, with a volume of 91,612 shares changing hands.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Needham & Company LLC started coverage on iRadimed in a research note on Tuesday, September 22nd. They set a "hold" rating for the company. Wall Street Zen cut shares of iRadimed from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Weiss Ratings cut shares of iRadimed from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $120.00.

iRadimed Stock Performance

The company has a 50 day moving average of $86.43 and a 200 day moving average of $90.79. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of 47.98 and a beta of 0.91.

iRadimed (NASDAQ:IRMD - Get Free Report) last announced its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.02. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. The company had revenue of $20.47 million for the quarter, compared to analysts' expectations of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, equities analysts predict that iRadimed Corporation will post 1.98 EPS for the current fiscal year.

iRadimed Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 28th. Investors of record on Friday, August 14th were paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, August 14th. iRadimed's dividend payout ratio is currently 44.69%.

Insider Buying and Selling

In other iRadimed news, Director Monty K. Allen sold 1,419 shares of the firm's stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total value of $122,615.79. Following the transaction, the director directly owned 19,581 shares of the company's stock, valued at $1,691,994.21. This trade represents a 6.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 34.60% of the company's stock.

Institutional Investors Weigh In On iRadimed

Large investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in shares of iRadimed during the 2nd quarter worth $92,485,000. Dimensional Fund Advisors LP increased its position in iRadimed by 4.2% during the first quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider's stock worth $21,768,000 after purchasing an additional 9,017 shares during the last quarter. Ranger Investment Management L.P. purchased a new position in iRadimed during the second quarter worth about $9,398,000. Bank of New York Mellon Corp purchased a new position in iRadimed during the second quarter worth about $7,252,000. Finally, Sei Investments Co. boosted its holdings in iRadimed by 17.2% in the 1st quarter. Sei Investments Co. now owns 74,304 shares of the medical equipment provider's stock valued at $7,153,000 after purchasing an additional 10,908 shares during the last quarter. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

iRadimed Company Profile

IRadimed Corporation develops, manufactures and markets medical devices designed for use in magnetic resonance imaging (MRI) environments. The company focuses on addressing the challenges of providing continuous infusion therapy and patient monitoring while patients are undergoing MRI procedures.

Its products include the MRidium MRI-compatible infusion pump system, which is designed to deliver intravenous medications and fluids without interfering with MRI operations, and MRI-compatible patient-monitoring systems used to track vital signs during imaging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.